Hemorrhoid Treatment Devices Market Value to Reach Around USD 870 billion by 2026: Acumen Research and Consulting
/
Date13 Apr 2019
Email Print Friendly Share LOS ANGELES, April 13, 2019 (GLOBE NEWSWIRE) — The global Hemorrhoid Treatment Devices market is anticipated to grow at a constant... Read More →
Albireo Presents Data on A4250 in Children with Biliary Atresia and Alagille Syndrome at The International Liver Congress 2019
/
Date13 Apr 2019
Email Print Friendly Share – Reduction in serum bile acids and pruritus observed in both populations – – Alagille abstract selected for inclusion in ’Best of... Read More →
Faircourt Asset Management Inc. Announces April Distributions
/
Date13 Apr 2019
Email Print Friendly Share TORONTO, April 12, 2019 (GLOBE NEWSWIRE) — Faircourt Asset Management Inc., as Manager of the Faircourt Funds (TSX:FGX), (TSX:FCS.UN), is pleased... Read More →
Royal Financial, Inc. Announces Third Quarter and Year to Date Earnings for Fiscal Year 2019
/
Date13 Apr 2019
Email Print Friendly Share CHICAGO, April 12, 2019 (GLOBE NEWSWIRE) — Royal Financial, Inc. (the “Company”) (OTCQX: RYFL), incorporated under the laws of Delaware on... Read More →
AKVA group ASA: buyback of own shares
/
Date13 Apr 2019
Email Print Friendly Share On 12 April 2019 AKVA group ASA (“AKVA group” or the “Company”) purchased 891 of its own shares under the buyback... Read More →
ACL Named One of Canada's Top Small & Medium Employers for Fifth Year in a Row
/
Date13 Apr 2019
Email Print Friendly Share Vancouver, BC, April 12, 2019 (GLOBE NEWSWIRE) — ACL, one of Canada’s most prominent tech companies, has been selected for the... Read More →
Anoto Group AB (publ) publicerar sin årsredovisning för 2018
/
Date13 Apr 2019
Email Print Friendly Share Stockholm, 12 april 2019 – Anoto Group AB (publ), org. nr 556532-3929, publicerar idag sin årsredovisning för 2018 på http://www.anoto.com/investors/reports/. En digital... Read More →
Assembly Biosciences Presents Interim Data from Two Phase 2a Studies of ABI-H0731 in HBV-Infected Subjects in a Late-Breaker Oral Session at EASL 2019
/
Date13 Apr 2019
Email Print Friendly Share – Favorable safety and tolerability profile– Superior antiviral activity with ABI-H0731 in combination with nucleos(t)ide therapies– Selected for inclusion in “Best... Read More →
Pinehurst Capital II Inc. Completes Initial Public Offering; Common Shares Will Commence Trading
/
Date13 Apr 2019
Email Print Friendly Share TORONTO, April 10, 2019 (GLOBE NEWSWIRE) — Pinehurst Capital II Inc. (TSXV: PINH.P) (the “Corporation“) is pleased to announce that it... Read More →